SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance

SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance

Therapeutic responses to identical chemotherapy regimens often vary significantly among patients with the same type of cancer, underscoring the need for additional biomarkers to identify individuals most likely to benefit from specific treatments. The expression of SLFN11 (Schlafen11) has been ident...

Full description

Saved in:
Bibliographic Details
Main Authors: Kunzhong Zhou, Yuewen Li, Weifang Wang, Yilin Chen, Bingyan Qian, Yiteng Liang, Hongmei Li, Ruiting Xu, Li Zhuang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-07-01
Series:Frontiers in Oncology
Subjects:
Schlafen11 (SLFN11)
DNA damaging agents
PARP inhibitors
pan-cancer
DNA damage repair mechanisms
epigenetics
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1582738/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items